These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35731101)

  • 1. Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer: A Prospective Study.
    Bernardi D; Vatteroni G; Acquaviva A; Valentini M; Sabatino V; Bolengo I; Pellegrini M; Fantò C; Trimboli RM
    AJR Am J Roentgenol; 2022 Dec; 219(6):884-894. PubMed ID: 35731101
    [No Abstract]   [Full Text] [Related]  

  • 2. Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis.
    Ploumen RAW; de Mooij CM; Gommers S; Keymeulen KBMI; Smidt ML; van Nijnatten TJA
    Eur Radiol; 2023 Aug; 33(8):5423-5435. PubMed ID: 37020070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast-enhanced mammography in the assessment of residual disease after neoadjuvant treatment.
    Hogan MP; Horvat JV; Ross DS; Sevilimedu V; Jochelson MS; Kirstein LJ; Goldfarb SB; Comstock CE; Sung JS
    Breast Cancer Res Treat; 2023 Apr; 198(2):349-359. PubMed ID: 36754936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of contrast-enhanced mammography in the preoperative detection of ductal carcinoma in situ of the breasts: a comparison with low-energy image and magnetic resonance imaging.
    Wang L; Wang P; Shao H; Li J; Yang Q
    Eur Radiol; 2024 May; 34(5):3342-3351. PubMed ID: 37853174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrast-Enhanced Mammography (CEM) for Detecting Residual Disease after Neoadjuvant Chemotherapy: A Comparison with Breast Magnetic Resonance Imaging (MRI).
    Barra FR; Sobrinho AB; Barra RR; Magalhães MT; Aguiar LR; de Albuquerque GFL; Costa RP; Farage L; Pratesi R
    Biomed Res Int; 2018; 2018():8531916. PubMed ID: 30533440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head-to-head comparison of contrast-enhanced mammography and contrast-enhanced MRI for assessing pathological complete response to neoadjuvant therapy in patients with breast cancer: a meta-analysis.
    Kaiyin M; Lingling T; Leilei T; Wenjia L; Bin J
    Breast Cancer Res Treat; 2023 Nov; 202(1):1-9. PubMed ID: 37615793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Performance of MRI, Molecular Breast Imaging, and Contrast-enhanced Mammography in Women with Newly Diagnosed Breast Cancer.
    Sumkin JH; Berg WA; Carter GJ; Bandos AI; Chough DM; Ganott MA; Hakim CM; Kelly AE; Zuley ML; Houshmand G; Anello MI; Gur D
    Radiology; 2019 Dec; 293(3):531-540. PubMed ID: 31660801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient perspectives on repeated contrast-enhanced mammography and magnetic resonance during neoadjuvant chemotherapy of breast cancer.
    Pires-Gonçalves L; Henriques Abreu M; Ferrão A; Guimarães Dos Santos A; Aguiar AT; Gouvêa M; Henrique R
    Acta Radiol; 2023 May; 64(5):1816-1822. PubMed ID: 36575580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is contrast-enhanced mammography (CEM) an alternative to MRI in assessing the response to primary systemic therapy of breast cancer?
    Sunen I; Isabel Garcia Barrado A; Cruz Ciria S; Garcia Maroto J; Gros Bañeres B; Garcia Mur C
    Eur J Radiol; 2024 Jan; 170():111270. PubMed ID: 38141263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging.
    Iotti V; Ravaioli S; Vacondio R; Coriani C; Caffarri S; Sghedoni R; Nitrosi A; Ragazzi M; Gasparini E; Masini C; Bisagni G; Falco G; Ferrari G; Braglia L; Del Prato A; Malavolti I; Ginocchi V; Pattacini P
    Breast Cancer Res; 2017 Sep; 19(1):106. PubMed ID: 28893303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy and precision of contrast enhanced mammography versus MRI for predicting breast cancer size: how "good" are they really?
    Taylor DB; Burrows S; Dessauvagie BF; Saunders CM; Ives A
    Br J Radiol; 2023 Mar; 96(1144):20211172. PubMed ID: 36753450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrast-Enhanced Mammography in Local Staging of Screen-Detected Breast Cancer.
    MacCallum C; Elder K; Nickson C; Ruecker K; Park A; Mann GB; Rose AK
    Ann Surg Oncol; 2024 Oct; 31(10):6820-6830. PubMed ID: 39048901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Performance in Diagnosis and Characterization of Breast Lesions: Contrast-Enhanced Mammography Versus Breast Magnetic Resonance Imaging.
    Açar ÇR; Orguc S
    Clin Breast Cancer; 2024 Aug; 24(6):481-493. PubMed ID: 38777678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrast-Enhanced Mammography (CEM) compared to Breast Magnetic Resonance (MRI) in the evaluation of breast lobular neoplasia.
    Nicosia L; Rotili A; Pesapane F; Bozzini AC; Battaglia O; Pellegrino G; Fusco N; Porta FM; Frassoni S; Bagnardi V; Corso G; Sangalli C; Cassano E
    Breast Cancer Res Treat; 2024 Jan; 203(1):135-143. PubMed ID: 37787819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy.
    Londero V; Bazzocchi M; Del Frate C; Puglisi F; Di Loreto C; Francescutti G; Zuiani C
    Eur Radiol; 2004 Aug; 14(8):1371-9. PubMed ID: 14986052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting Upgrade of Ductal Carcinoma In Situ to Invasive Breast Cancer at Surgery With Ultrafast Imaging.
    Miceli R; Gao Y; Qian K; Heller SL
    AJR Am J Roentgenol; 2023 Jul; 221(1):34-43. PubMed ID: 36752370
    [No Abstract]   [Full Text] [Related]  

  • 17. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
    Scheel JR; Kim E; Partridge SC; Lehman CD; Rosen MA; Bernreuter WK; Pisano ED; Marques HS; Morris EA; Weatherall PT; Polin SM; Newstead GM; Esserman LJ; Schnall MD; Hylton NM;
    AJR Am J Roentgenol; 2018 Jun; 210(6):1376-1385. PubMed ID: 29708782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic contrast-enhanced mammography and breast MRI in the diagnosis of breast cancer and detection of tumor size.
    Tekinhatun M; Sabir N; Erdem E; Yilmaz S; Ufuk F
    Turk J Med Sci; 2024; 54(1):249-261. PubMed ID: 38812642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abbreviated Versus Full-Protocol MRI for Breast Cancer Neoadjuvant Chemotherapy Response Assessment: Diagnostic Performance by General and Breast Radiologists.
    Tang WJ; Chen SY; Hu WK; Li XL; Zheng BJ; Wang ZS; Ding HJ; Chen LX; Zhang QQ; Yu XM; Sui Y; Wei XH; Guo Y
    AJR Am J Roentgenol; 2023 Jun; 220(6):817-825. PubMed ID: 36752371
    [No Abstract]   [Full Text] [Related]  

  • 20. Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?
    Thompson BM; Chala LF; Shimizu C; Mano MS; Filassi JR; Geyer FC; Torres US; de Mello GGN; da Costa Leite C
    Eur Radiol; 2022 Mar; 32(3):1663-1675. PubMed ID: 34716780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.